# Lexeo Trial Data Leads Raymond James and Cantor Fitzgerald to Raise Targets

By Token Post

Canonical URL: https://www.tokenpost.com/news/insights/58725
Published: 2026-11-16T19:13:15.000Z
Updated: 2026-11-16T19:13:15.000Z
Section: Insights & Views

> The target changes followed interim data from a Phase I/II trial of LX2020 for PKP2 arrhythmogenic cardiomyopathy. Raymond James views Lexeo as a strong buy.

Raymond James and Cantor Fitzgerald raised their price targets for Lexeo Therapeutics (LXEO) after interim data from a Phase I/II trial of LX2020 for PKP2 arrhythmogenic cardiomyopathy.

Raymond James views Lexeo as a strong buy.


